ARVINAS, INC. (ARVN) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $164.10M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$63.80M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$43.80M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$71.50M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $164.10M | (m) | $249.70M | (m) | $200.00K* | -$48.30M* | (m) | $52.60M | (m) | $200.00K |
| 2026-03-31 | Reported | (m) | -$63.80M | (m) | $15.60M | (m) | $1.30M | -$69.20M | (m) | $60.30M | (m) | $100.00K |
| 2025-09-30 | Reported | (m) | -$43.80M | (m) | (m) | (m) | $100.00K* | -$59.10M* | (m) | $64.70M | (m) | $300.00K |
| 2025-06-30 | Reported | (m) | -$71.50M | (m) | $22.40M | (m) | $1.20M* | -$95.40M* | (m) | $68.60M | (m) | -$300.00K |
| 2025-03-31 | Reported | (m) | $71.40M | (m) | $188.80M | (m) | $400.00K | -$88.90M | (m) | $90.80M | (m) | $200.00K |
| 2024-09-30 | Reported | (m) | -$60.30M | (m) | (m) | (m) | $700.00K* | -$128.00M* | (m) | $86.90M | (m) | $600.00K |
| 2024-06-30 | Reported | (m) | -$48.50M | (m) | (m) | (m) | $700.00K* | $50.30M* | (m) | $93.70M | (m) | $200.00K |
| 2024-03-31 | Reported | (m) | -$83.30M | (m) | (m) | (m) | $100.00K | -$97.50M | (m) | $84.30M | (m) | $100.00K |
| 2023-09-30 | Reported | (m) | -$73.90M | (m) | (m) | (m) | $1.10M* | -$84.80M* | (m) | $85.90M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$74.60M | (m) | (m) | (m) | $600.00K* | -$88.70M* | (m) | $103.40M | (m) | -$300.00K |
| 2023-03-31 | Reported | (m) | -$87.70M | (m) | (m) | (m) | $1.10M | -$91.20M | (m) | $95.30M | (m) | -$400.00K |
| 2022-09-30 | Reported | (m) | -$64.30M | (m) | (m) | (m) | $2.20M* | -$66.60M* | (m) | $77.50M | (m) | $2.20M |
| 2022-06-30 | Reported | (m) | -$65.80M | (m) | (m) | (m) | $1.40M* | -$78.60M* | (m) | $75.30M | (m) | $3.40M |
| 2022-03-31 | Reported | (m) | -$57.70M | (m) | (m) | (m) | $2.10M | -$57.10M | (m) | $64.00M | (m) | $4.50M |
| 2021-09-30 | Reported | (m) | -$47.30M | (m) | $9.20M* | (m) | $1.30M* | $681.50M* | (m) | $40.60M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$51.90M | (m) | $5.60M* | (m) | $500.00K* | -$47.40M* | (m) | $43.00M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | -$41.70M | (m) | $5.50M | (m) | $1.00M | -$39.00M | (m) | $34.90M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$31.75M | (m) | $7.50M* | (m) | $1.41M* | -$22.38M* | (m) | $30.01M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$26.48M | (m) | $5.80M* | (m) | $1.82M* | -$21.40M* | (m) | $23.42M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$23.41M | (m) | $6.20M | (m) | $1.36M | -$16.95M | (m) | $21.73M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$22.79M | (m) | (m) | (m) | (m) | (m) | (m) | $20.41M | (m) | (m) |
| 2019-09-30 | Reported | (m) | $5.50M | (m) | $5.40M* | (m) | $1.19M* | $1.85M* | (m) | $16.59M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$18.42M | (m) | $4.00M* | (m) | $2.89M* | -$13.57M* | (m) | $16.00M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$15.81M | (m) | $4.00M | (m) | $380.64K | -$12.73M | (m) | $14.19M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$16.94M | (m) | (m) | (m) | (m) | (m) | (m) | $14.56M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$14.06M | (m) | (m) | (m) | $938.89K* | -$10.99M* | (m) | $13.15M | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$8.52M | (m) | (m) | (m) | $631.58K* | -$12.18M* | (m) | $10.34M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$4.28M | (m) | (m) | (m) | $638.64K | $19.30M | (m) | $7.14M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$5.31M | (m) | (m) | (m) | (m) | (m) | (m) | $6.69M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$6.41M | (m) | (m) | (m) | (m) | (m) | (m) | $7.22M | (m) | $0.00 |
| 2017-06-30 | Reported | (m) | -$6.72M | (m) | (m) | (m) | (m) | (m) | (m) | $7.82M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$6.32M | (m) | (m) | (m) | (m) | (m) | (m) | $7.06M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$118.50M | (m) | (m) | (m) | $1.90M | -$273.80M | (m) | $285.20M | (m) | $300.00K |
| 2024-12-31 | Reported | (m) | -$250.20M | (m) | (m) | (m) | $1.80M | -$259.30M | (m) | $348.20M | (m) | $600.00K |
| 2023-12-31 | Reported | (m) | -$401.50M | (m) | (m) | (m) | $2.90M | -$347.80M | (m) | $379.70M | (m) | $900.00K |
| 2022-12-31 | Reported | (m) | -$263.20M | (m) | (m) | (m) | $6.80M | -$273.50M | (m) | $315.00M | (m) | $20.90M |
| 2021-12-31 | Reported | (m) | -$188.40M | (m) | $46.70M | (m) | $4.70M | $559.40M | (m) | $180.40M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$120.80M | (m) | $21.80M | (m) | $6.40M | -$89.70M | (m) | $108.40M | (m) | $0.00 |
| 2020-09-30 | Rolling | (m) | -$104.43M* | (m) | (m) | (m) | (m) | (m) | (m) | $95.57M* | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$67.18M* | (m) | (m) | (m) | (m) | (m) | (m) | $82.15M* | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$59.12M* | (m) | (m) | (m) | (m) | (m) | (m) | $74.73M* | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$51.50M | (m) | $18.30M | (m) | $6.30M | -$40.60M | (m) | $67.20M | (m) | $0.00 |
| 2019-12-31 | Rolling | (m) | -$51.52M* | (m) | (m) | (m) | (m) | (m) | (m) | $67.19M* | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$45.68M* | (m) | (m) | (m) | (m) | (m) | (m) | $61.34M* | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$65.24M* | (m) | (m) | (m) | (m) | (m) | (m) | $57.90M* | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$55.33M* | (m) | (m) | (m) | (m) | (m) | (m) | $52.24M* | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$43.80M | (m) | $14.30M | (m) | $2.83M | -$16.12M | (m) | $45.19M | (m) | $0.00 |
| 2018-12-31 | Rolling | (m) | -$43.80M* | (m) | (m) | (m) | (m) | (m) | (m) | $45.19M* | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$32.17M* | (m) | (m) | (m) | (m) | (m) | (m) | $37.32M* | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$24.52M* | (m) | (m) | (m) | (m) | (m) | (m) | $31.39M* | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$22.73M* | (m) | (m) | (m) | (m) | (m) | (m) | $28.88M* | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$24.76M | (m) | (m) | (m) | $1.01M | $5.11M | (m) | $28.79M | (m) | $0.00 |
| 2017-12-31 | Rolling | (m) | -$24.76M* | (m) | (m) | (m) | (m) | (m) | (m) | $28.79M* | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |